We are pleased to announce that the second AIT module is dedicated to the latest advances.
The module focuses on the potential economic benefits of AIT, both for the patient and the society. Recognising the importance of pharmaco-economics in the context of AIT, we delve into the financial implications of allergy treatments, providing an essential perspective for informed decision-making in clinical practice.

In addition, the module sheds light on the role of how eHealth technologies can support AIT’s prescription, administration and monitoring from basics to future potential, along with concrete clinical examples.
We also discuss the methodological aspect of AIT clinical trials, such as real-world studies involving populations not well represented in randomised controlled trials (RCTs).

Important topics, such as the combination of AIT and biologicals for long-term effect and sustainability, and novel preparations and adjuvants used in AIT, are thoroughly examined in this module.
See how symptom assessment of patients might be performed with allergic rhinitis using an Allergen Exposure Chamber.

This module is supported by an unrestricted grant from Stallergenes Greer and Inmunotek.